Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: A review

Clinical Transplantation

Volumn 19, Issue 6, 2005, Pages 705-710

  Sandrini, Silvio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Basiliximab; Daclizumab; Delayed graft function; Interleukin 2; Renal transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; NEPHROTOXICITY; PRESCRIPTION; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; REVIEW; RISK REDUCTION;

ANTIBODIES, MONOCLONAL; CALCINEURIN; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RECOVERY OF FUNCTION; TIME FACTORS;

EID: 28644435097     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00417.x     Document Type: Review

References (40)

1. Sola R, Alarcon A, Jimenez C, Osuna A. The influence of delayed graft function. Nephrol Dial Transplant 2004: 19(Suppl. 3): III32.
2. Ojo AO, Wolfe RA, Held PJ, Port FK, Shmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997: 63: 968.
3. Leggat JE Jr, Ojo AO, Leichtman AB et al. Long-term renal allograft survival: prognostic implication of timing of acute rejection episodes. Transplantation 1997: 63: 1268.
4. Mateu LM, Calabuig A, Plaza CL, Esteve FA. Acute rejection and late renal transplant failure: risk factors and prognosis. Nephrol Dial Transplant 2004: 19(Suppl. 3): III38.
5. Hagenmeyer E-G, Haussler B, Hempel E et al. Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities and complications. Transplantation 2004: 77: 1545.
6. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996: 50: 1089.
7. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987: 44: 135.
8. Emparan C, Laukotter M, Wolters H, Dame C, Heidenreich S, Senninger N. Calcineurin-free protocols with basiliximab induction allow patients included in 'old to old' programs to achieve standard kidney transplant function. Transplant Proc 2003: 35: 1326.
9. Meier-Kriesche H-U, Schold JD, Srinivas TR, Reed A, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004: 4: 378.
10. Bunnapradist S, Takemoto SK. Multivariate analysis of antibody induction therapy. Chapter 32. In: Cecka JM, Terasaki PI eds. Clinical Transplants. Los Angeles, California, USA: UCLA Immunogenetics Center, 2003.
11. Nashan B. The interleukin-2 inhibitors and their role in low-toxicity regimens. Transplant Proc 1999: 31(Suppl. 8A): 23S.
12. Nashan B, Moore R, Amlot P et al. for the CHIB 201 International Study Group. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997: 350: 1193.
13. Kahan BD, Rajagopalan PR, Hall M, for the United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999: 67: 276.
14. Ponticelli C, Yussim A, Cambi V et al. on behalf of the Simulect Phase IV Study Group. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001: 72: 1261.
15. Lawen JG, Davies EA, Mourad G et al. on behalf of the Simulect International Study Group. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003: 75: 37.
16. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999: 67: 110.
17. Vicenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998: 338: 1700.
18. Leonardi G, Messina M, Giraudi R, Pellu V, Fop F, Segoloni GP. Basiliximab in association with tacrolimus and steroids in Caucasian cadaveric renal transplanted patients: significant decrease in early acute rejection rate and hospitalization time. Clin Transplant 2004: 18: 113.
19. Lebranchu Y, Bridoux F, Buchler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002: 2: 48.
20. Sollinger H, Kaplan B, Pescovitz MD et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001: 72: 1915.
21. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004: 77: 166.
22. Chowdhury S, Kode RK, Ranganna K et al. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid-sparing and more effective than OKT3. Transplant Proc 2001: 33: 1057.
23. Brennan D, Thymoglobulin Induction Study Group. Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: final results from a prospective, randomized, multicenter trial. Am J Transplant 2003: 3(Suppl 5): 438.
24. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. Br Med J 2003: 326: 789.
25. Hengster P, Pescovitz MD, Hyatt D, Margreitter R. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Transplantation 1999: 68: 310.
26. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004: 4: 222.
27. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with post-transplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003: 76: 1289.
28. Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003: 17: 234.
29. Tran HT, Acharya MK, McKay DB et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000: 11: 1903.
30. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001: 71: 1282.
31. Batiuk TD, Bennett WM, Norman DJ. Cytokine nephropathy during antilymphocyte therapy. Transplant Proc 1993: 25(Suppl. 1): 27.
32. Boletis JN, Theodoropoulou T, Hiras D et al. Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression. Transplant Proc 2001: 33: 3184.
33. Shidban H, Sabawi M, Aswad S et al. Controlled trial of IL-2R antibody basiliximab (Simulect) vs low dose OKT3 in cadaver kidney transplant recipients. Transplantation 2000: 69: S156 (Abstract 164).
34. Heifets M, Saeed MI, Moritz MJ. Induction with basiliximab (Simulect) in elderly recipients of kidney transplants allows improved safety, reduced rejection, and lower cost when compared to anti-lymphocyte globulin (ATGAM) and Monomurab (OKT-3). Am J Transplant 2004: 4(Suppl. 8): 348.
35. Parrott NR, Hammad AQ, Watson CJE, Lodge PJA, Andrews CD. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine A monotherapy in renal transplant recipients. Transplantation 2005: 79: 344.
36. Bunnapradist S, Lochlainn EN, Takemoto SK. Antibody induction therapy and their associated outcomes in cadaveric kidney transplants. Am J Transplant 2004: 4(Suppl. 8): 264.
37. Lilliu H, Brun-Strang C, Le Pen C et al. Cost-minimization study comparing Simulect vs thymoglobulin in renal transplant induction. Clin Transplant 2004: 18: 247.
38. Vicenti F, Light J, Pearson T et al. Is it necessary to withhold Neoral (CsA) therapy during delayed graft function in renal transplant recipients? Am J Transplant 2004: 4(Suppl. 8): 488.
39. Hartle JE, Bisordi JE, Chao S, Freeland MJ, West JC. The addition of basiliximab to Cellcept, Neoral and steroids resulted in a significant reduction in acute real allograft rejection. Transplantation 2000: 69(Suppl. 8): S159.
40. Goggins WC, Pascual MA, Powelson JA et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003: 76: 798.